Search

Displaying results 4191 - 4200 of 10000 in total
  1. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

    Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide
  2. Drug

    CERE-120

    go.drugbank.com/drugs/DB05637
    Investigational

    CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. … It was under investigation in clinical trials for the treatment of Parkinson's Disease.

  3. Drug

    TB-402

    go.drugbank.com/drugs/DB06050
    Investigational

    TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. … It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.

  4. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models

  5. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

  6. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  7. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). … a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.

  8. Drug

    ATL1102

    go.drugbank.com/drugs/DB04997
    Investigational

    ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

  9. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    In the United States camazepam is regulated as a Schedule IV controlled substance. … Similarly to other drugs in its class, it has antxiolytic, anticonvulsant, hypnotic, and skeletal muscle relaxant properties.

  10. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses. … Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.